These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18485383)

  • 41. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population.
    Gokden N; Roehl KA; Catalona WJ; Humphrey PA
    Urology; 2005 Mar; 65(3):538-42. PubMed ID: 15780372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?
    Scattoni V; Roscigno M; Raber M; Dehò F; Maga T; Zanoni M; Riva M; Sangalli M; Nava L; Mazzoccoli B; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    J Urol; 2008 Apr; 179(4):1327-31; discussion 1331. PubMed ID: 18289580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
    Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
    BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
    Walz J; Graefen M; Chun FK; Erbersdobler A; Haese A; Steuber T; Schlomm T; Huland H; Karakiewicz PI
    Eur Urol; 2006 Sep; 50(3):498-505. PubMed ID: 16631303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
    Jeong IG; Lee KH;
    J Urol; 2008 Jan; 179(1):111-6. PubMed ID: 17997422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
    Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
    Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
    Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
    Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.
    Gallo F; Chiono L; Gastaldi E; Venturino E; Giberti C
    Urology; 2008 Sep; 72(3):628-32. PubMed ID: 18279918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets.
    Utsumi T; Kawamura K; Suzuki H; Kamiya N; Imamoto T; Miura J; Ueda T; Maruoka M; Sekita N; Mikami K; Ichikawa T
    Int J Urol; 2009 Apr; 16(4):416-9. PubMed ID: 19226358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Kumar A; Godoy G; Taneja SS
    Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer.
    Briganti A; Gallina A; Suardi N; Chun FK; Walz J; Heuer R; Salonia A; Haese A; Perrotte P; Valiquette L; Graefen M; Rigatti P; Montorsi F; Huland H; Karakiewicz PI
    BJU Int; 2008 Mar; 101(5):556-60. PubMed ID: 18005204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.